PL3344654T3 - Przeciwciała anty-lag-3 - Google Patents
Przeciwciała anty-lag-3Info
- Publication number
- PL3344654T3 PL3344654T3 PL16759785T PL16759785T PL3344654T3 PL 3344654 T3 PL3344654 T3 PL 3344654T3 PL 16759785 T PL16759785 T PL 16759785T PL 16759785 T PL16759785 T PL 16759785T PL 3344654 T3 PL3344654 T3 PL 3344654T3
- Authority
- PL
- Poland
- Prior art keywords
- lag
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1515572.4A GB201515572D0 (en) | 2015-09-02 | 2015-09-02 | Anti-LAG-3 antibodies |
GBGB1612437.2A GB201612437D0 (en) | 2016-07-18 | 2016-07-18 | Anti-lag-3 antibodies |
EP16759785.5A EP3344654B1 (en) | 2015-09-02 | 2016-09-01 | Anti-lag-3 antibodies |
PCT/EP2016/070664 WO2017037203A1 (en) | 2015-09-02 | 2016-09-01 | Anti-LAG-3 Antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3344654T3 true PL3344654T3 (pl) | 2021-05-17 |
Family
ID=56852278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL16759785T PL3344654T3 (pl) | 2015-09-02 | 2016-09-01 | Przeciwciała anty-lag-3 |
Country Status (20)
Country | Link |
---|---|
US (2) | US11680104B2 (pl) |
EP (2) | EP3798234A1 (pl) |
JP (3) | JP7074341B2 (pl) |
KR (1) | KR20180042412A (pl) |
CN (2) | CN108699145A (pl) |
AU (2) | AU2016316730B2 (pl) |
BR (1) | BR112018004181A2 (pl) |
CA (1) | CA2995639A1 (pl) |
DK (1) | DK3344654T3 (pl) |
ES (1) | ES2842306T3 (pl) |
HK (1) | HK1256116A1 (pl) |
IL (1) | IL257798B1 (pl) |
MX (2) | MX2018002610A (pl) |
PH (1) | PH12018500369A1 (pl) |
PL (1) | PL3344654T3 (pl) |
PT (1) | PT3344654T (pl) |
RU (2) | RU2760582C2 (pl) |
SG (1) | SG10201913864RA (pl) |
WO (1) | WO2017037203A1 (pl) |
ZA (1) | ZA201801432B (pl) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
IL257798B1 (en) * | 2015-09-02 | 2024-06-01 | Immutep Sas | Antibodies against LAG-3 |
CR20180161A (es) | 2015-10-02 | 2018-05-25 | Hoffmann La Roche | Anticuerpos biespecíficos para pd1 y tim3 |
TW201803905A (zh) | 2016-06-20 | 2018-02-01 | 克馬伯有限公司 | 用於免疫腫瘤學之多重專一性抗體 |
CN117586403A (zh) | 2016-10-11 | 2024-02-23 | 艾吉纳斯公司 | 抗lag-3抗体及其使用方法 |
BR112019017329A2 (pt) | 2017-04-03 | 2020-04-14 | Hoffmann La Roche | imunoconjugados, um ou mais polinucleotídeos e vetores, métodos para a produção de um imunoconjugado, tratamento de uma doença e para a estimulação do sistema imunológico, composição, uso do imunoconjugado, invenção e usos da composição |
EP4112644A1 (en) * | 2017-04-05 | 2023-01-04 | F. Hoffmann-La Roche AG | Anti-lag3 antibodies |
AU2018247794A1 (en) | 2017-04-05 | 2019-08-22 | F. Hoffmann-La Roche Ag | Bispecific antibodies specifically binding to PD1 and LAG3 |
US20220135670A1 (en) * | 2017-04-27 | 2022-05-05 | Tesaro, Inc. | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
EP3618871A4 (en) | 2017-05-02 | 2021-01-06 | Merck Sharp & Dohme Corp. | ANTI-LAG3 ANTIBODIES ETCO-FORMULATIONS ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
CN110720039A (zh) | 2017-05-30 | 2020-01-21 | 百时美施贵宝公司 | Lag-3阳性肿瘤的治疗 |
WO2018222722A2 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
CA3073733A1 (en) * | 2017-08-30 | 2019-03-07 | Phanes Therapeutics, Inc. | Anti-lag-3 antibodies and uses thereof |
RU2771384C2 (ru) * | 2017-12-22 | 2022-05-04 | Цзянсу Хэнжуй Медсин Ко., Лтд. | Фармацевтическая композиция, содержащая антитело к lag-3, и ее применение |
CN109970856B (zh) | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
WO2019129137A1 (zh) * | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
EP3768720A4 (en) * | 2018-03-20 | 2022-01-05 | Wuxi Biologics Ireland Limited | NEW ANTI-LAG-3 ANTIBODY POLYPEPTIDE |
US20210077477A1 (en) * | 2018-03-27 | 2021-03-18 | Raz Yirmiya | Microglia modulators for use in treatment of depression |
CN110343178B (zh) * | 2018-04-03 | 2022-07-22 | 上海开拓者生物医药有限公司 | 抗人lag-3单克隆抗体及其应用 |
CN110606892B (zh) * | 2018-06-14 | 2023-09-26 | 华博生物医药技术(上海)有限公司 | 一种高亲和力高生物活性的lag-3抗体及其应用 |
CN111620949A (zh) * | 2019-02-28 | 2020-09-04 | 三生国健药业(上海)股份有限公司 | 结合人lag-3的抗体、其制备方法和用途 |
GB201906127D0 (en) | 2019-05-01 | 2019-06-12 | Immutep S A | Assays |
GB201906118D0 (en) | 2019-05-01 | 2019-06-12 | Immutep S A | Anti-LAG-3 binding molecules |
EP3969040A1 (en) | 2019-05-13 | 2022-03-23 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
EP3984554A4 (en) * | 2019-06-11 | 2023-11-08 | ONO Pharmaceutical Co., Ltd. | IMMUNOSUPPRESSION AGENT |
KR20220164548A (ko) * | 2020-04-03 | 2022-12-13 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Lag3에 결합하는 조작된 항체 |
EP4157879A4 (en) * | 2020-05-27 | 2024-06-19 | Agilent Technologies, Inc. | HUMAN ANTI-LAG-3 ANTIBODIES AND THEIR USE IN IMMUNOHISTOCHEMISTRY (IHC) |
EP4196502A1 (en) | 2020-08-13 | 2023-06-21 | Bristol-Myers Squibb Company | Methods of redirecting of il-2 to target cells of interest |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US4666884A (en) | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4866132A (en) | 1986-04-17 | 1989-09-12 | The Research Foundation Of State University Of New York | Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5256334A (en) | 1988-09-08 | 1993-10-26 | The Research Foundation Of The State University Of New York | Homogeneous radiopaque polymer-organobismuth composites |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5976877A (en) | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
ATE158615T1 (de) | 1990-03-20 | 1997-10-15 | Univ Columbia | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
JP3534749B2 (ja) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
ES2165851T3 (es) | 1991-11-25 | 2002-04-01 | Enzon Inc | Proteinas multivalentes que se unen a antigenos. |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
US5346981A (en) | 1993-01-13 | 1994-09-13 | Miles Inc. | Radiopaque polyurethanes |
CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
CN1263864C (zh) | 1993-10-25 | 2006-07-12 | 坎吉公司 | 重组腺病毒载体及其使用方法 |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
DK0796341T3 (da) | 1994-12-09 | 1999-06-14 | Imp College Innovations Ltd | Identifikation af gener, som tillader tilpasning af en mikroorganisme til en særlig omgivelse |
US5939045A (en) | 1994-12-22 | 1999-08-17 | Nissan Chemical Industries, Ltd. | Organic bismuth derivatives for X-ray imaging |
US5958713A (en) | 1995-01-31 | 1999-09-28 | Novo Nordisk A/S | Method of detecting biologically active substances by using green fluorescent protein |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
AU701375B2 (en) | 1995-07-21 | 1999-01-28 | Institut Gustave Roussy | Methods for detecting, identifying, isolating, and selectively labelling and targeting Th1 lymphocytes by means of the LAG-3 protein |
US5968738A (en) | 1995-12-06 | 1999-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Two-reporter FACS analysis of mammalian cells using green fluorescent proteins |
US6020192A (en) | 1996-01-18 | 2000-02-01 | University Of Florida | Humanized green fluorescent protein genes and methods |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
CA2249998A1 (en) | 1996-03-27 | 1997-10-02 | Crc For Biopharmaceutical Research Pty. Ltd. | The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias |
WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
TW371617B (en) | 1996-10-09 | 1999-10-11 | Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau | Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
US7259247B1 (en) | 1997-09-23 | 2007-08-21 | Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes | Anti-human T-cell costimulating polypeptide monoclonal antibodies |
JP2001525470A (ja) | 1997-12-12 | 2001-12-11 | マクロメド・インコーポレーテッド | タンパク修飾のためのヘテロ官能化星形ポリ(エチレングリコール) |
PL199659B1 (pl) | 1998-02-25 | 2008-10-31 | Merck Patent Gmbh | Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2 |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
WO2000009560A2 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
US5985577A (en) | 1998-10-14 | 1999-11-16 | The Trustees Of Columbia University In The City Of New York | Protein conjugates containing multimers of green fluorescent protein |
MXPA01007170A (es) | 1999-01-15 | 2002-07-30 | Genentech Inc | Variantes de polipeptidos con funcion efectora alterada. |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
JP3597140B2 (ja) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途 |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US6374470B1 (en) | 2000-10-06 | 2002-04-23 | Milliken & Company | Face plate for spun-like textured yarn |
JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン,エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
IL160170A0 (en) | 2001-08-03 | 2004-07-25 | Glycart Biotechnology Ag | A host cell engineered to produce a polypeptide having increased cytotoxicity |
WO2005077042A2 (en) | 2004-02-09 | 2005-08-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
AU2003210806A1 (en) | 2002-03-05 | 2003-09-22 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
JP2006523226A (ja) | 2003-02-28 | 2006-10-12 | ザ ジョンズ ホプキンス ユニバーシティ | T細胞調節方法 |
PT1639011E (pt) | 2003-06-30 | 2009-01-20 | Domantis Ltd | Anticorpos (dab) de domínio único peguilados |
US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
CA2562764A1 (en) | 2004-04-23 | 2005-11-03 | Richard Kroczek | Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo |
BRPI0512235A (pt) | 2004-06-18 | 2008-02-19 | Ambrx Inc | polipeptìdeos ligadores de antìgenos e seus usos |
AU2005269759A1 (en) | 2004-07-21 | 2006-02-09 | Glycofi, Inc. | Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform |
CA2573359A1 (en) | 2004-07-22 | 2006-02-02 | Genentech, Inc. | Method of treating sjogren's syndrome |
US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
JP4997108B2 (ja) | 2005-07-22 | 2012-08-08 | 協和発酵キリン株式会社 | 遺伝子組換え抗体組成物 |
US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
US9585957B2 (en) | 2007-09-07 | 2017-03-07 | The Johns Hopkins University | Adenosine receptor agonists and antagonists to modulate T cell responses |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
AR077594A1 (es) | 2009-07-31 | 2011-09-07 | Organon Nv | Anticuerpos completamente humanos para btla (atenuante de linfocitos b y t) |
ES2624835T3 (es) | 2009-08-06 | 2017-07-17 | Immunas Pharma, Inc. | Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
ES2618586T3 (es) | 2010-09-16 | 2017-06-21 | Baliopharm Ag | Anticuerpo anti-huTNFR1 |
WO2013022091A1 (ja) | 2011-08-11 | 2013-02-14 | 小野薬品工業株式会社 | Pd-1アゴニストからなる自己免疫疾患治療剤 |
UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
PL2970464T3 (pl) | 2013-03-15 | 2020-10-05 | Glaxosmithkline Intellectual Property Development Limited | Wiążące białka anty-lag-3 |
KR20240110004A (ko) | 2014-03-14 | 2024-07-12 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
IL257798B1 (en) * | 2015-09-02 | 2024-06-01 | Immutep Sas | Antibodies against LAG-3 |
-
2016
- 2016-09-01 IL IL257798A patent/IL257798B1/en unknown
- 2016-09-01 RU RU2018111508A patent/RU2760582C2/ru active
- 2016-09-01 KR KR1020187008670A patent/KR20180042412A/ko not_active Application Discontinuation
- 2016-09-01 RU RU2021133819A patent/RU2021133819A/ru unknown
- 2016-09-01 DK DK16759785.5T patent/DK3344654T3/da active
- 2016-09-01 EP EP20197814.5A patent/EP3798234A1/en active Pending
- 2016-09-01 WO PCT/EP2016/070664 patent/WO2017037203A1/en active Application Filing
- 2016-09-01 EP EP16759785.5A patent/EP3344654B1/en active Active
- 2016-09-01 CN CN201680064139.XA patent/CN108699145A/zh active Pending
- 2016-09-01 MX MX2018002610A patent/MX2018002610A/es unknown
- 2016-09-01 JP JP2018511202A patent/JP7074341B2/ja active Active
- 2016-09-01 PT PT167597855T patent/PT3344654T/pt unknown
- 2016-09-01 PL PL16759785T patent/PL3344654T3/pl unknown
- 2016-09-01 AU AU2016316730A patent/AU2016316730B2/en active Active
- 2016-09-01 CN CN202311238293.2A patent/CN117510633A/zh active Pending
- 2016-09-01 SG SG10201913864RA patent/SG10201913864RA/en unknown
- 2016-09-01 BR BR112018004181A patent/BR112018004181A2/pt active Search and Examination
- 2016-09-01 CA CA2995639A patent/CA2995639A1/en active Pending
- 2016-09-01 ES ES16759785T patent/ES2842306T3/es active Active
- 2016-09-01 US US15/756,767 patent/US11680104B2/en active Active
-
2018
- 2018-02-19 PH PH12018500369A patent/PH12018500369A1/en unknown
- 2018-03-01 ZA ZA2018/01432A patent/ZA201801432B/en unknown
- 2018-03-01 MX MX2023001226A patent/MX2023001226A/es unknown
- 2018-11-27 HK HK18115194.2A patent/HK1256116A1/zh unknown
-
2021
- 2021-03-15 JP JP2021041608A patent/JP2021097706A/ja active Pending
-
2022
- 2022-07-14 JP JP2022113055A patent/JP2022137218A/ja not_active Withdrawn
-
2023
- 2023-05-05 US US18/312,629 patent/US20230272107A1/en active Pending
- 2023-07-11 AU AU2023204589A patent/AU2023204589A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1253507A1 (zh) | 抗 ror1 抗體 | |
HK1254836A1 (zh) | 抗-ror1抗體 | |
HK1256116A1 (zh) | 抗lag-3抗體 | |
IL253633A0 (en) | Anti-transthyretin antibodies | |
GB201521393D0 (en) | Antibodies | |
GB201521391D0 (en) | Antibodies | |
HK1246804A1 (zh) | Tau結合抗體 | |
GB201521382D0 (en) | Antibodies | |
ZA201705662B (en) | Anti-transthyretin antibodies | |
IL255323A0 (en) | Anti-fcrn antibodies | |
HK1255056A1 (zh) | 抗cd115抗體 | |
SG11201706126WA (en) | Anti-transthyretin antibodies | |
GB201509907D0 (en) | Antibodies | |
GB201522394D0 (en) | Antibodies | |
GB201503438D0 (en) | Antibodies | |
IL284022A (en) | Anti-transthyretin antibodies | |
GB201518728D0 (en) | Antibodies | |
GB201515572D0 (en) | Anti-LAG-3 antibodies | |
GB201515570D0 (en) | Anti-LAG-3 antibodies | |
GB201514425D0 (en) | Antibodies | |
GB201508444D0 (en) | Antibodies | |
GB201508437D0 (en) | Antibodies | |
GB201507541D0 (en) | Antibodies | |
GB201504858D0 (en) | Antibodies | |
GB201502591D0 (en) | Antibodies |